T-Cell Trafficking Facilitated by High Endothelial Venules Is Required for Tumor Control After Regulatory T-Cell Depletion
Total Page:16
File Type:pdf, Size:1020Kb
Published OnlineFirst September 7, 2012; DOI: 10.1158/0008-5472.CAN-12-1912 Cancer Microenvironment and Immunology Research T-Cell Trafficking Facilitated by High Endothelial Venules Is Required for Tumor Control after Regulatory T-Cell Depletion James P. Hindley1, Emma Jones1, Kathryn Smart1, Hayley Bridgeman1, Sarah N. Lauder1, Beatrice Ondondo1, Scott Cutting1, Kristin Ladell1, Katherine K. Wynn1, David Withers2, David A. Price1, Ann Ager1, Andrew J. Godkin1, and Awen M. Gallimore1 Abstract The evolution of immune blockades in tumors limits successful antitumor immunity, but the mechanisms underlying this process are not fully understood. Depletion of regulatory T cells (Treg), a T-cell subset that dampens excessive inflammatory and autoreactive responses, can allow activation of tumor-specific T cells. However, cancer immunotherapy studies have shown that a persistent failure of activated lymphocytes to infiltrate tumors remains a fundamental problem. In evaluating this issue, we found that despite an increase in T- cell activation and proliferation following Treg depletion, there was no significant association with tumor growth rate. In contrast, there was a highly significant association between low tumor growth rate and the extent of T-cell infiltration. Further analyses revealed a total concordance between low tumor growth rate, high T-cell infiltration, and the presence of high endothelial venules (HEV). HEV are blood vessels normally found in secondary lymphoid tissue where they are specialized for lymphocyte recruitment. Thus, our findings suggest that Treg depletion may promote HEV neogenesis, facilitating increased lymphocyte infiltration and destruction of the tumor tissue. These findings are important as they point to a hitherto unidentified role of Tregs, the manipulation of which may refine strategies for more effective cancer immunotherapy. Cancer Res; 72(21); 5473–82. Ó2012 AACR. þ Introduction CD8 T-cell response and slower tumor growth. Use of the þ þ þ Several laboratories have shown that CD4 CD25 Foxp3 DTR-Foxp3 transgenic mice has also shown that Treg deple- regulatory T cells (Treg), which normally serve to control tion can prevent development and even limit the progression of fl tumors induced by the carcinogen methylcholanthrene (MCA) autoimmunity and in ammation, also inhibit immune þ responses to tumor antigens (1). Thus, strategies aimed at in a manner that is dependent on CD8 T cells and IFNg (8). boosting antitumor responses, through manipulation of Tregs, The success of these interventions however remains sub- are being intensely investigated. In mice, prophylactic deple- optimal. Treg depletion, even when combined with vaccina- tion of Tregs using CD25-specific antibodies can limit and tion, does not readily result in the elimination of established even prevent tumor development and/or progression (2–4). tumors as tumor rejection is often observed in only a pro- The development of transgenic mice expressing the primate portion of treated mice. Several factors, including the extent of þ fi diphtheria toxin receptor (DTR) on Foxp3 cells has allowed T-cell activation and/or tumor in ltration, may account for specific and complete depletion of Tregs by administration of this failure (6). In this study, we set out to identify factors diphtheria toxin (DT; 5). Using the melanoma cell line B16, it limiting the success of antitumor immune responses. For this purpose, we used the MCA chemical carcinogenesis model in has been shown that selective Treg depletion using anti-CD25 DTR antibodies (6) or DT (7) results in activation of a tumor-specific combination with Foxp3 mice (5), to identify the key features that distinguish progressing tumors from those that are controlled after Treg depletion. Our findings clearly Authors' Affiliations: 1Infection and Immunity, School of Medicine, Henry indicate that T-cell infiltration and not the extent of acti- 2 Wellcome Building, Cardiff University, Cardiff, United Kingdom; and MRC vation, is a critical bottleneck to tumor destruction in Treg- Centre for Immune Regulation, Institute for Biomedical Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, depleted animals. Moreover, our extensive immunohisto- United Kingdom chemical analyses of MCA-induced tumors from Treg- Note: Supplementary data for this article are available at Cancer Research replete and Treg-depleted mice revealed that control of Online (http://cancerres.aacrjournals.org/). tumor growth, observed in Treg-depleted mice, was deter- mined by development of high endothelial venules (HEV), J.P. Hindley and E. Jones have contributed equally to this work. specialized blood vessels that alter both the composition Corresponding Author: Awen M. Gallimore, Infection and Immunity, fi School of Medicine, Henry Wellcome Building, Cardiff University, Cardiff, and size of the T-cell in ltrate (9, 10). Overall, these data CF144XN, United Kingdom. Phone: 44-2920-687012; Fax: 44-2920- provide a new perspective on the impact of Treg depletion, 687079; E-mail: [email protected] demonstrating that Tregs control immune responses, not doi: 10.1158/0008-5472.CAN-12-1912 only through limiting immune activation, but also through Ó2012 American Association for Cancer Research. influencing blood vessel differentiation. www.aacrjournals.org 5473 Downloaded from cancerres.aacrjournals.org on October 3, 2021. © 2012 American Association for Cancer Research. Published OnlineFirst September 7, 2012; DOI: 10.1158/0008-5472.CAN-12-1912 Hindley et al. Materials and Methods Immunohistochemistry Paraffin sections. Mice Tumors were collected from DTR fi We are grateful to Professor Alexander Rudensky for sup- Foxp3 mice and xed in neutral buffered formalin and fi plying Foxp3DTR mice. These were backcrossed with C57BL/6 embedded in paraf n. Sections 5 mm in thickness, were cut mice for 5 or more generations and housed in accordance with and mounted on slides, dewaxed in xylene and hydrated UK Home Office regulations. using graded alcohols to tap water. After conducting antigen retrieval, by microwaving in 10 mmol/L Tris, 1 mmol/L EDTA buffer pH9 for 8 minutes, sections were cooled for Tumor induction, DT administration, and tumor 30 minutes and then equilibrated in PBS. Endogenous per- monitoring oxidase activity was quenched with Peroxidase Suppressor DTR Foxp3 mice were injected subcutaneously in the left hind (Thermo Scientific) for 15 minutes and nonspecificantibody leg with 400 mg of 3-MCA (Sigma-Aldrich) in 100 mL of olive oil binding was blocked by incubating sections with 2.5% nor- under general anesthetic as described previously (11). Mice mal horse serum (VectorLabs) in PBS for 30 minutes. Sec- were monitored for tumor development weekly up to 2 months tions were stained overnight at 4C with the following and daily thereafter. Tumor-bearing mice were culled before primary antibodies diluted in 1% bovine serum albumin their tumors reached 1.7 cm in diameter, typically 80 to 150 (BSA) in PBS: rat antiperipheral node addressin (PNAd) days after injection or if tumors caused discomfort. DT (Sigma) antibody (clone MECA-79; Biolegend) and rat anti-Mucosal diluted in PBS was administered intraperitoneally (i.p.) every addressin cell adhesion molecule-1 (MAdCAM-1) antibody other day after tumor detection. (clone MECA-367; Biolegend). Primary antibodies were À1 Tumor growth rate (k, days ) was determined using a stat- detected with anti-rat Immpress (VectorLabs) for 30 min- istical software package Prism 5 (GraphPad) with the following utes and visualized with impact 3,30-diaminobenzidine (Vec- ¼ Â Â equation for exponential growth: Y Y0 exp(k X). Tumor torLabs). Sections were counterstained with haematoxylin, diameter (X, mm) was measured every 2 days using calipers. On dehydrated in an ethanol series, and mounted in distyrene, average, measurements were taken for 12 days for PBS-treated plasticizer, xylene. Photomicrographs were taken using a mice and 17 days for DT-treated mice. Therefore, on average 6 NIKON microscope and digital camera. to 8 measurements were used to calculate tumor growth rate. Frozen sections. Tumors and lymph nodes were collected from Foxp3DTR mice, embedded in optimum cutting temper- Flow cytometry ature compound (OCT; RA Lamb), and snap frozen in liquid Single-cell suspensions of spleens, inguinal lymph nodes, nitrogen. Sections, 5 mm in thickness, were fixed for 10 minutes and tumors were prepared. The inguinal lymph node from the in ice-cold acetone and left to dry at room temperature. Slides tumor (left) side was taken as the tumor-draining lymph node were washed in PBS and blocked with Avidin/Biotin Blocking and the contralateral inguinal lymph node as a nondraining Kit (VectorLabs) and then 2.5% normal horse serum (Vector- lymph node. Labs) in PBS for 30 minutes. Sections were stained overnight at For analysis of intracellular cytokines by flow cytometry, 4C with the following primary antibodies diluted in 1% BSA in single-cell suspensions were stimulated with 20 ng/ml phor- PBS: rat anti-PNAd antibody (clone MECA-79; Biolegend), bol myristate acetate (Sigma-Aldrich) and 1 mg/mL ionomycin Alexa Fluor 488 rat anti-MAdCAM-1 antibody (clone MECA- (Sigma-Aldrich). Cells were incubated at 37 C for a total of 4 367; BioLegend), biotin rat anti-PNAd antibody (clone MECA- hours. After 1 hour, 1 mL/mL of GolgiStop (containing mon- 79; BioLegend), rat anti-CD4 (clone RM4–5; eBioscience), rat ensin; Becton Dickinson) was added to each well. anti-CD8 (clone 53–6.7; eBioscience), fluorescein isothiocya-